A process for the preparation of argatroban monohydrate with a diastereoisomeric ratio of about 65:35 comprising following steps; a. hydrogenating 2R, 4R-4-methyl-1[N2-(3-methyl- 8- quinolinesulfonyl)-L-arginyl-2-piperidine carboxylic acid (I) to 2R, 4R-4-methyl-1 [N2-(3-methyl-1 ,2, 3,4-tetrahydro-8- quinolinesulfo...

A novel process for preparing Fulvestrant (XV) comprising following steps; (h) treating the diacetate of formula (VIII) with base in hydroxylated solvent to hydrolyse and obtain 7a-(9-hydroxynonyl)oestra-1,3,5 (10)-triene-3,17-diol(XVI); XVI (i) protecting the phenolic group in the triol (XVI) obtained in step (a) w...

The present relates to process for preparation of pralatrexate which act as anti cancer agent.

The present invention relates to process for the preparation of highly pure Cabazitaxel monohydrate, more particularly crystalline form of Cabazitaxel monohydrate in which the organic solvents used in the process are controlled well with in the ICH limits and hence considered safe and the pharmaceutical compositions...

A process for the production and purification of PTH (1-34) comprising of: a. Production of fusion protein CBD-PTH {1-34) by fermentation employing recombinant E.coli having the plasmid for expression of the fusion protein wherein a DNA fragment coding for a polypeptide PTH (1-34) is fused to a DNA fragment coding ...

Abstract A stable composition comprising 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propionic acid monohydrochloride monohydrate (Tirofiban hydrochloride) as active pharmaceutical ingredient and method for the preparation is disclosed. The composition exhibits an improved chromatographic pro...

A stable intramuscular formulation comprising 7-

A novel process for the preparation of Dipivefrin Hydrochloride (I) which acts as an antiglaucoma and broncholytic agent.

ABSTRACT The present invention provides improved process for preparation of arteether under reaction conditions that improve reaction yields and facilitate the process. In particular, the present invention is directed to the synthesis of p-arteether wherein the said process facilitates 90% formation P-arteether an...

A process for preparing a compound represented as compound-ll comprising, (i) acetylating compound - I using an acetylating agent in an organic solvent to obtain the compound -II, (ii) washing the compound obtained in step (i) with water to remove impurities (iii) evaporating the resultin...

The present invention is related to a novel process for the preparation of cisatracurium besylaie, more particularly optically and geometrically pure cisatracurium besylate in large scale.

The present invention is related to a novel process for the preparation of Pemetrexed disodium hemipentahydrate, which acts as a chemotherapy drug for the treatment of pleural mesothelioma as well as non-small cell lung cancer.

Polymorphic Form of Bortezomib in Form I, From II, Amorphous Form and process for the preparation their of is disclosed.

Stable sustained release pharmaceutical preparations of ranolazine dihydrochloride are disclosed in which the active ingredient is present in a soluble and easy to prepare salt form. The sustained release of the active ingredient is achieved by employing a matrix tablet (coated or uncoated) containing a non-ionic bi...

1.  A process for the preparation of Anidulafungin which comprising the following steps; a)  treating 4"-(Pentyloxy)-l, r:4",l"-terphenyl-4-carboxylic acid with 2-Chloro-4,6-dimethoxy-l,3,5-triazine (CDMT) in a solvent with base to prepare compound of Formula II; (2-({[4"-(Pentyloxy)-l, l":4",l"-terphenyl-4-yl]carb...

A process for the preparation of pure Regadenoson comprising; a. dissolving impure Regadenoson in a mixture of at least one solvent selected form the group consisting of amides, sulphoxide and at least one solvent selected from the group consisting of alcohol; b. treating the solution obtained in step(a) with on...

The present invention provides a stable dear colorless liquid composition comprising Calcitriol w„h butylated hydros toiuene and/ or butylated hydroxy anisole; further this invention provides innovative liquid composition of Calcitriol.

CURCUMIN is a naturally occurring secondary plant metabolite having several useful pharmacological activities, angiostatic activity being one of them. Curcumin is insoluble in water and generally cannot be easily and effectively administered through oral, parenteral, topical, ophthalmic, or other routes. Folkman ...

The present invention provides a stable ready to use liquid pharmaceutical composition comprising Ziprasidone or its pharmaceutical!)' acceptable salts and cyclodextrin or its derivatives and a process for the preparation thereof. Further, the present invention provides stable ready to use composition of Ziprasidone...

The present invention provides a stable pharmaceutical composition of trabectedin comprising trabectedin or its pharmaceutically acceptable salt and bulking agent. The composition further comprising pH adjusting agent, buffer and other pharmaceutically acceptable excipients. The present invention also provides a pro...

The present invention provides a process for the preparation of cangrelor (I) or its pharmaceutically acceptable salts and intermediates thereof. The process provides industrially and economically viable process for the preparation of cangrelor (I) or its pharmaceutically acceptable salts.

Abstract PROCESS FOR PREPARATION OF HIGHLY PURE SUGAMMADEX OR ITS"S PHARMACEUTICALLY ACCEPTABLE SALTS AND INTERMEDIATES THEREOF The present invention relates to a process for preparation of highly pure Sugammadex or its pharmaceutically acceptable salts and intermediates thereof. The present invention also invol...

Anecortave (3), 17a, 21-Dihydroxy-pregna-4, 9(1 l)-diene-3,20-dione, is a synthetic Steroid having angiostatic activity. Folkman et al observed enhanccmcnt of angiostatic activity of a number of Steroids in the presence of heparin or its fragmcnts. The present invention relates to investigation of the effect of hepa...

The present invention relates to identification, characterization and synthesis of impurities which are formed during the synthesis and/or degradation of Regadenoson. The present invention is useful to develop analytical method to monitor all the impurities and control those impurities to be well within the ICH limi...

The present invention relates to a process for the preparation of aripiprazole lauroxil. Further, the process of the present invention provides highly pure aripiprazole lauroxil. The present invention also provides a process for preparation of sterile aripiprazole lauroxil which can be directly used in the preparati...

The present invention provides a stable pharmaceutical composition containing anliemelic agents selected from S-HTs antagonist and Neurokinin I (NK1) receptor antagonist. Specifically, the present invention provides a stable pharmaceutical composition comprising Palonosetron or its salt. Fosnetupitant or its salt an...

The present invention provides a parenteral pharmaceutical compositions comprising bendamustine. More particularly, the present invention relates to parenteral compositions of bendamustine in the form of liquid and /or solution.

ABSTRACT AN IMPROVED PROCESS FOR PREPARATION OF PURE LACOSAMIDE The present invention provides an improved process for preparation of pure lacosamide and intermediates thereof. The process of the present invention provides lacosamide and intermediates thereof having high enantiomeric purity. ...

A PROCESS FOR PREPARATION OF HIGHLY PURE EDARAVONE The present invention provides a process for preparation of edaravone. The process according to the present invention involves a reaction of phenylhydrazine with alkylacetoacetate followed by adjusting the pH of the reaction mass between 7.5 and 8.0 using acid to o...

ABSTRACT A STABLE PHARMACEUTICAL COMPOSITION COMPRISING EDARAVONE PROVIDED IN A POLYMERIC CONTAINER The present invention provides a pharmaceutical composition comprising edaravone, wherein the composition is provided in a sealed container comprises three layered film. The three layered film container of the prese...

The present invention provides a process for the preparation of netarsudil or its pharmaceutical^ acceptable salts. The present invention further provides an amorphous form of netarsudil dimesylate and its process for preparation.

The present invention provides an improved process for preparation of crystalline Form-S of Regadenoson using a mixture of organic solvents by simple and industrially feasible methods to obtain regadenoson having pharmaceutically acceptable level of residual solvents.

ABSTRACT PROCESS FOR THE PREPARATION OF REMIMAZOLAM SALTS AND ITS POLYMORPHS The present invention provides a stable amorphous form of Remimazolam tosylate and process for its preparation by simple and industrially feasible methods. The present invention also provides crystalline Form-G of Remimazolam Tosylate c...

ABSTRACT The present invention provides a simple, novel and industrially feasible process for the preparation of Remimazolam intermediate of following structural formula; [D] The present invention also provides an improved process for the preparation of Remimazolam or its pharmaceutically acceptable salts of f...